Qiagen stock holds mid-40 dollar level as analysts stick to hold ratings

Qiagen stock is trading in the low-40 dollar range as of August 31, 2026, while recent quarterly figures and a patent verdict against a subsidiary shape how analysts and investors assess the diagnostics group.

Qiagen N.V. (ISIN NL0012169213) stock is quoted around 43.23 USD as of August 31, 2026 according to a market-data snapshot that also shows a market capitalization of 8.926 billion USD, keeping the diagnostics specialist firmly in the mid-cap bracket for investors watching valuation levels.

Analysts highlight recent earnings beat

According to a consensus overview compiled by MarketBeat on September 1, 2026, Qiagen stock carries an average 12-month price target of 43.93 USD and an overall hold rating, only a small premium to the reported share price of 43.35 USD as of that snapshot and signaling limited implied upside in the current analyst view.

The same analysis notes that Qiagen most recently reported quarterly earnings per share of 0.62 USD on revenue of 535.04 million USD for a quarter that ended within the last 12 months, modestly ahead of the 0.60 USD EPS consensus and 527.50 million USD revenue estimate, which means the company beat expectations by 0.02 USD per share and about 7.54 million USD in sales.

Revenue growth and margins in focus

In that latest quarter, Qiagen generated net margin of 19.49 percent and return on equity of 14.47 percent according to the MarketBeat consensus detail, underscoring that the company is converting almost one fifth of its revenue into net income while delivering mid-teens returns on shareholder capital in the most recently reported period.

The same quarterly comparison shows that earnings per share in the latest quarter rose from 0.60 USD in the prior year period to 0.62 USD, an increase of 0.02 USD per share, while revenue grew from a slightly lower base to 535.04 million USD, described as an increase of 0.2 percent year on year, highlighting that profit improvement outpaced the modest top line gain.

Legal verdict adds to risk perception

A separate legal development also features in the current Qiagen story after a federal jury in the US District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen, willfully infringed three patents licensed to Scale Biosciences, which 10x Genomics acquired in 2025, according to a report by AllSci dated September 1, 2026.

The Delaware jury awarded 10x Genomics 4.8 million USD in damages based on a 14 percent royalty rate on relevant sales of Parse Evercode Whole Transcriptome products from February 2021 through June 30, 2026, and this ruling underscores how patent disputes can affect Qiagen subsidiaries even when the sums involved are relatively modest compared with group revenue.

Qiagen stock and peer comparison

Market data compiled in late August 2026 show Qiagen shares referenced in a narrow band between 43.23 USD and 43.29 USD as of August 31, 2026 and early September 1, 2026, which means the stock is trading just below the 43.93 USD average analyst price target cited by the MarketBeat consensus and indicates that the current market price already reflects much of the expected near term performance.

In broader diagnostics and research peer context, Castle Biosciences is cited in a Yahoo Finance overview with its own Q2 fiscal 2026 revenue of 103.55 million USD and a reported share price of 33.44 USD as of a recent close, while Qiagen is listed in the same data feed at 43.39 USD, suggesting that Qiagen trades at a higher absolute share price but operates on a substantially larger revenue base, which helps explain why market capitalization for Qiagen sits near 8.926 billion USD compared with the smaller US peer.

Qiagen sample preparation and assay portfolio

Qiagen is best known for its portfolio of sample preparation kits and molecular diagnostic assays that support workflows in laboratories worldwide, including DNA and RNA extraction products used in research and clinical settings to prepare biological samples for downstream analysis in PCR and next generation sequencing instruments.

The company also markets a range of automated platforms that integrate sample preparation and detection for applications such as infectious disease testing and oncology, giving it exposure to both routine diagnostic volumes and higher value testing segments, which can drive revenue growth when new assays gain regulatory clearance and are adopted by laboratories.

Stock remains in mid-40 dollar range

As of the late August and early September 2026 pricing snapshots referenced above, Qiagen stock remains in the low to mid 40 USD range around 43.23 USD to 43.39 USD on its primary US listing on the New York Stock Exchange under the ticker QGEN, which aligns with a mid-cap diagnostics valuation and provides a reference level for investors monitoring future quarterly results and legal developments.

Qiagen stock at a glance

• Company: Qiagen N.V.
• ISIN: NL0012169213
• Ticker: QGEN
• Trading venue: NYSE
• Price (as of August 31, 2026): 43.23 USD
• Market capitalization: 8.926 billion USD (as of August 31, 2026)
• Sector / Industry: Health care / Diagnostics and research
• Index membership: None of the major DAX or SMI indices